Parkinson Prize

The Journal of Parkinson's Disease (JPD) is pleased to announce the launch of the Parkinson Prize, coinciding with the anniversary celebrations commemorating the first 10 volumes of the journal. In the future, every year the Associate Editors of the journal will select the best article from the previous year's volumes. As this is the first occasion, the award period will cover the first years of the journal and a prize will be awarded for the best research article and one for the best review article. The awardee(s) will receive a Parkinson Prize trophy and a cash prize of $1,000 in recognition of outstanding contribution to the advancement of Parkinson’s disease research. The Parkinson Prize is presented by JPD and IOS Press.

Details of the winners of the Parkinson Prize 2020 are outlined below, along with the runners-up of each prize. The Editors-in-Chief Patrik Brundin, MD, PhD, and Bastiaan Bloem, MD, PhD, comment: "The entire Editorial Board is delighted to formally recognize these important contributions to the literature on Parkinson’s disease and is honored to have the opportunity to publish such significant work in the journal."

Read the press release here


Winning research article: Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease (2014), Aviles-Olmos I, Dickson, J, Kefalopoulou, Z, Djamshidian, A, Kahan, J, Ell, P, Whitton, P, Wyse, R, Isaacs, T, Lees, A, Limousin, P, Foltynie, J Parkinsons Dis, Vol.4, 337–344.

Importance of the work: The Foltynie study adds confidence that the potential beneficial effects of exenatide for the treatment of PD may be related to more than transient symptomatic benefits. The trial participants who used exenatide for one year as part of the investigators’ first trial were reviewed a year after stopping exenatide, and their "off dopaminergic medication" video assessments remained improved compared to the participants who were randomly assigned to the control group. "We have learned that careful long-term follow-up can be hugely instructive and have embraced the long-term follow up strategy in the evaluation of exenatide in our current phase 3 trial. My co-investigators and I are very honored that the Journal of Parkinson's Disease has chosen to recognize this article in this way," commented Prof. Foltynie.

Thomas Foltynie, MD, PhD, Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London. Prof. Foltynie is responsible for movement disorder patients, particularly PD patients, undergoing advanced treatments such as deep brain stimulation (DBS), apomorphine, and duodopa. He is chief investigator for a series of trials of exenatide, a potential neurorestorative treatment for PD, as well as the lead clinician at UCL for trials of alpha synuclein antibody treatment for PD and Oxford BioMedica / Axovant’s gene therapy product for PD, and the Transeuro PD cell transplantation program.


Winning review article: Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff (2017), Braak, H, Del Tredici, K, J Parkinsons Dis, Vol.7, S71–S85.

Importance of the work: Prof. Braak and Dr. Del Tredici review the development and rationale for the six-stage staging model they proposed for brain pathology related to sporadic Parkinson's disease (Neurobiol Aging 2003) and ensuing controversies. This staging model continues to fuel discussions as well as new hypotheses and new experimental models pertaining to the pathogenesis and pathomechanisms of Parkinson's disease. "Neuropathological staging of protein misfolding disorders helps to provide insights into the regional distribution of pathology, its potential systemic spread or propagation along neuroanatomical connectivities, and the selective vulnerability of specific types of neuronal and non-neuronal cells, whereby the prion-like concept of the synucleinopathy and the theory of selective vulnerability in Parkinson's disease are by no means mutually exclusive," explained Prof. Braak and Dr. Del Tredici. "We would like to thank the Journal of Parkinson's Disease Editorial Board members for their recognition of our work."

Heiko Braak, MD, a native of Kiel, completed medical school at the University of Kiel, receiving his doctorate in 1964. After the habilitation in anatomy (1970), he became Professor of Anatomy in Kiel (1974). As Visiting Professor of Neurology at Harvard Medical School (1978), he worked with Prof. Norman Geschwind and published the monograph Architectonics of the Human Telencephalic Cortex (1980). He directed the Institute for Clinical Neuroanatomy, Dr. Senckenberg Anatomical Institute at Goethe University Frankfurt/Main (1980–2002). After retiring from university teaching, he was appointed Guest Researcher (2002–2009) at the Anatomical Institute until moving to Ulm University (2009), where he is Senior Professor and co-group leader of the Section Clinical Neuroanatomy (Department of Neurology, Center for Biomedical Research).

Kelly Del Tredici, MD, PhD, a native of San Francisco, came to Germany on a Frederick Sheldon Traveling Fellowship from Harvard University (1989) after studying at Loyola University of Chicago and Fordham University. She completed medical school at the Goethe University Frankfurt/Main, receiving her doctorate in anatomy there in 2004. Following medical residency at the Clinic for Psychiatry and Neurology in Winnenden (near Stuttgart), she became a postdoctoral fellow at the Dr. Senckenberg Anatomical Institute (Institute for Clinical Neuroanatomy, Goethe University) in 2006. She moved to Ulm University (2009), where she is co-group leader of the Section Clinical Neuroanatomy (Department of Neurology, Center for Biomedical Research). She is a member of Phi Beta Kappa. Her research interests include neuroanatomy, neurodegeneration, Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis.




  • Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents (2018), Polinski NK, Volpicelli-Daley LA, Sortwell CE, et al., J Parkinsons Dis, Vol.8, 303–322
  • Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease (2012), Khoo SK, Petillo D, Kang UJ, et al., J Parkinsons Dis, Vol.2, 321–331
  • Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease (2019), Whone AL, Boca M, Luz M, et al., J Parkinsons Dis, Vol.9, 301–313
  • Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies (2016), Pagan F, Hebron M, Valadez EH, et al., J Parkinsons Dis, 2016, Vol.6, 503–517


  • The Synaptic Function of α-Synuclein (2015), Burré J, J Parkinsons Dis, Vol.5, 699–713
  • The Emerging Evidence of the Parkinson Pandemic (2018), Dorsey ER, Sherer T, Okun MS, Bloem BR, J Parkinsons Dis<.em>, Vol.8, S3–S8
  • The Role of Innate and Adaptive Immunity in Parkinson's Disease (2013), Kannarkat GT, Boss JM, Tansey MG, J Parkinsons Dis, Vol.3, 493–514
  • The Role of Oxidative Stress in Parkinson's Disease (2013), Dias V, Junn E, Mouradian MM, J Parkinsons Dis, Vol.3, 461–491

  • JPD is proud to host such high-quality work, and acknowledges the excellent contributions by these authors and all those who were in the running.